Q: What is Epclusa used for?

Epclusa is used to treat chronic hepatitis C virus infection .

Q: How does Epclusa work?

Mechanism of Action Epclusa contains two active ingredients, sofosbuvir and velpatasvir. These are known as direct-acting antivirals (DAAs) because they target the hepatitis C virus (HCV) directly to prevent it from making copies of itself. Each ingredient targets a specific protein the virus needs to survive and replicate: Sofosbuvir: This component is a nucleotide analog polymerase inhibitor. It blocks a protein called NS5B polymerase, which the virus uses to copy its genetic material (RNA). By inhibiting this process, sofosbuvir prevents the virus from reproducing. Velpatasvir: This component is an NS5A inhibitor. It targets the NS5A protein, which is necessary for the virus to assemble new viral particles and move them within the cell. By blocking these two distinct stages of the viral life cycle, the medication lowers the amount of hepatitis C virus in the body to undetectable levels. When the virus can no longer be detected in the blood for 12 weeks or more after finishing treatment, the infection is considered cured.

Q: What are the active ingredients in Epclusa?

The active ingredients in Epclusa are sofosbuvir and velpatasvir .

Q: What are the side effects of Epclusa?

Common side effects of Epclusa may include: Headache Fatigue Nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is Epclusa?

Epclusa belongs to the HCV NS5B polymerase and NS5A inhibitors drug class.

Q: What is the dosage of Epclusa and how do I take it?

How to Take Epclusa Epclusa is available as tablets or oral pellets. It is usually taken once a day at the same time each day. You may take this medication with or without food. Administration Instructions Tablets: Swallow the tablet whole. Oral Pellets: Pellets can be swallowed whole or sprinkled on a small amount of non-acidic soft food, such as pudding, chocolate syrup, or ice cream. If sprinkling on food, the mixture should be swallowed shortly after mixing without chewing the pellets. It is important to continue taking Epclusa for the entire length of time prescribed, even if you begin to feel better. Stopping the medication early may make the infection harder to treat. Missed Doses If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Q: Is Epclusa safe during pregnancy and breastfeeding?

Pregnancy There are no adequate studies on the use of Epclusa in pregnant women to determine if there is a risk of birth defects or miscarriage. In animal studies, no harm to the fetus was observed when the components of Epclusa were administered at high doses. However, because human data is limited, healthcare providers typically discuss the potential risks and benefits before starting treatment during pregnancy. It is important to note that if Epclusa is used in combination with ribavirin, the risks change significantly. Ribavirin is known to cause severe birth defects or the death of an unborn baby. If ribavirin is part of the treatment plan, pregnancy must be avoided by both female patients and the female partners of male patients during treatment and for at least six months after the last dose. Breastfeeding It is currently unknown whether the active ingredients in Epclusa, sofosbuvir and velpatasvir, pass into human breast milk or if they affect milk production. The safety of breastfeeding while taking this medication has not been established. Patients should discuss breastfeeding plans with their healthcare provider to weigh the benefits of breastfeeding against any potential risks to the infant.

Q: What is the FDA approval status of Epclusa?

FDA Approval and Indications Epclusa, a combination of sofosbuvir and velpatasvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) infection. It is indicated for patients with HCV genotypes 1, 2, 3, 4, 5, or 6. The medication is approved for use in adults and pediatric patients aged 3 years and older. The treatment regimen depends on the patient's liver function. Epclusa is used alone in patients without cirrhosis or with compensated cirrhosis. For patients with decompensated cirrhosis, it is approved for use in combination with ribavirin. Boxed Warning The FDA has issued a boxed warning for Epclusa concerning the risk of hepatitis B virus (HBV) reactivation. In patients coinfected with both HCV and HBV, starting treatment with direct-acting antivirals like Epclusa can cause the hepatitis B virus to become active again. This reactivation can lead to serious liver problems, including liver failure or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before initiating treatment. Regulatory Status Epclusa is not a controlled substance. There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication. It was the first all-oral, pan-genotypic single-tablet regimen approved by the FDA for the treatment of chronic hepatitis C.

Question 1

What is Epclusa?

Accepted Answer

Epclusa is a medication that contains two active ingredients, sofosbuvir and velpatasvir. These components belong to a class of drugs known as direct-acting antivirals, which are designed to target the hepatitis C virus directly.

The medication functions by interfering with specific proteins that the virus requires to replicate and survive. By inhibiting these processes, the treatment helps to lower the viral load in the body and supports the clearance of the infection.

Question 2

What is Epclusa used for?

Accepted Answer

Epclusa is used to treat chronic hepatitis C virus infection.

Question 3

How does Epclusa work?

Accepted Answer

Mechanism of Action

Epclusa contains two active ingredients, sofosbuvir and velpatasvir. These are known as direct-acting antivirals (DAAs) because they target the hepatitis C virus (HCV) directly to prevent it from making copies of itself.

Each ingredient targets a specific protein the virus needs to survive and replicate:

Sofosbuvir: This component is a nucleotide analog polymerase inhibitor. It blocks a protein called NS5B polymerase, which the virus uses to copy its genetic material (RNA). By inhibiting this process, sofosbuvir prevents the virus from reproducing.
Velpatasvir: This component is an NS5A inhibitor. It targets the NS5A protein, which is necessary for the virus to assemble new viral particles and move them within the cell.

By blocking these two distinct stages of the viral life cycle, the medication lowers the amount of hepatitis C virus in the body to undetectable levels. When the virus can no longer be detected in the blood for 12 weeks or more after finishing treatment, the infection is considered cured.

Question 4

What are the active ingredients in Epclusa?

Accepted Answer

The active ingredients in Epclusa are sofosbuvir and velpatasvir.

Question 5

What are the side effects of Epclusa?

Accepted Answer

Common side effects of Epclusa may include:

Headache
Fatigue
Nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Epclusa?

Accepted Answer

Epclusa belongs to the HCV NS5B polymerase and NS5A inhibitors drug class.

Question 7

What is the dosage of Epclusa and how do I take it?

Accepted Answer

How to Take Epclusa

Epclusa is available as tablets or oral pellets. It is usually taken once a day at the same time each day. You may take this medication with or without food.

Administration Instructions

Tablets: Swallow the tablet whole.
Oral Pellets: Pellets can be swallowed whole or sprinkled on a small amount of non-acidic soft food, such as pudding, chocolate syrup, or ice cream. If sprinkling on food, the mixture should be swallowed shortly after mixing without chewing the pellets.

It is important to continue taking Epclusa for the entire length of time prescribed, even if you begin to feel better. Stopping the medication early may make the infection harder to treat.

Missed Doses

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Question 8

Is Epclusa safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate studies on the use of Epclusa in pregnant women to determine if there is a risk of birth defects or miscarriage. In animal studies, no harm to the fetus was observed when the components of Epclusa were administered at high doses. However, because human data is limited, healthcare providers typically discuss the potential risks and benefits before starting treatment during pregnancy.

It is important to note that if Epclusa is used in combination with ribavirin, the risks change significantly. Ribavirin is known to cause severe birth defects or the death of an unborn baby. If ribavirin is part of the treatment plan, pregnancy must be avoided by both female patients and the female partners of male patients during treatment and for at least six months after the last dose.

Breastfeeding

It is currently unknown whether the active ingredients in Epclusa, sofosbuvir and velpatasvir, pass into human breast milk or if they affect milk production. The safety of breastfeeding while taking this medication has not been established. Patients should discuss breastfeeding plans with their healthcare provider to weigh the benefits of breastfeeding against any potential risks to the infant.

Question 9

What forms and strengths does Epclusa come in?

Accepted Answer

Epclusa is a fixed-dose combination medication provided in two primary oral formulations:

Oral Tablets: These are film-coated tablets intended to be swallowed whole.
Oral Pellets: These pellets are provided in packets. They are designed to be swallowed whole or sprinkled on a small amount of non-acidic soft food for patients who have difficulty swallowing tablets.

Question 10

What is the FDA approval status of Epclusa?

Accepted Answer

FDA Approval and Indications

Epclusa, a combination of sofosbuvir and velpatasvir, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) infection. It is indicated for patients with HCV genotypes 1, 2, 3, 4, 5, or 6. The medication is approved for use in adults and pediatric patients aged 3 years and older.

The treatment regimen depends on the patient's liver function. Epclusa is used alone in patients without cirrhosis or with compensated cirrhosis. For patients with decompensated cirrhosis, it is approved for use in combination with ribavirin.

Boxed Warning

The FDA has issued a boxed warning for Epclusa concerning the risk of hepatitis B virus (HBV) reactivation. In patients coinfected with both HCV and HBV, starting treatment with direct-acting antivirals like Epclusa can cause the hepatitis B virus to become active again. This reactivation can lead to serious liver problems, including liver failure or death. Healthcare providers are required to screen all patients for evidence of current or prior HBV infection before initiating treatment.

Regulatory Status

Epclusa is not a controlled substance. There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication. It was the first all-oral, pan-genotypic single-tablet regimen approved by the FDA for the treatment of chronic hepatitis C.

Question 11

What should I know about Epclusa and cost?

Accepted Answer

Factors Influencing Cost

The total price for a course of Epclusa can vary significantly based on several factors. Because it is a specialty medication, it is usually dispensed through specialty pharmacies rather than standard retail locations. Key factors include:

Insurance Coverage: Most private insurance plans, Medicare, and Medicaid provide coverage for this medication, though copays and deductibles vary. Some plans may require prior authorization.
Treatment Duration: A standard treatment course typically lasts 12 weeks, and the total cost is determined by the number of tablets required for the full duration.
Generic Availability: A generic version containing the same active ingredients (sofosbuvir and velpatasvir) is available and may be a more affordable option depending on your insurance provider's formulary.

Financial Assistance

Patients who are uninsured or have high out-of-pocket costs may be eligible for financial support. The manufacturer often provides patient assistance programs or copay coupons to help reduce expenses for eligible individuals. Additionally, some non-profit organizations offer grants to help cover the cost of chronic hepatitis C medications.

Epclusa

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Epclusa

Hospitals.net Disclosure